Cannabidiol — Hermetica Encyclopedia
Named Bioactive Compounds · Compound

Cannabidiol

Provisional Moderate Scorecannabinoid

Hermetica Superfood Encyclopedia

Evidence review status: unreviewed

Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.

Review flags: AWAITING_SEMANTIC_VALIDATION

Provisional Summary

Cannabidiol (CBD) is a non-psychoactive phytocannabinoid derived from Cannabis sativa that modulates the endocannabinoid system primarily through indirect antagonism of CB1 receptors and direct agonism of TRPV1 and serotonin 5-HT1A receptors. Its most rigorously demonstrated clinical application is reducing seizure frequency in treatment-resistant epilepsy syndromes such as Dravet and Lennox-Gastaut.

Screened PMID Records
Reported Benefits
Pending
Synergy Review
At a Glance
CategoryNamed Bioactive Compounds
GroupCompound
Public Score StatusProvisional Moderate
Primary Keywordcannabidiol benefits
Cannabidiol close-up macro showing natural texture and detail — rich in anxiolytic, anticonvulsant, anti-inflammatory
Cannabidiol — botanical close-up

Origin & History

Cannabidiol growing in natural environment — natural habitat
Natural habitat

Cannabidiol (CBD) is a non-psychoactive phytocannabinoid extracted from Cannabis sativa L. (industrial hemp varieties containing <0.3% THC), primarily from the plant's inflorescences. Commercial CBD is produced through supercritical CO₂ extraction followed by winterization, chromatography, and crystallization to yield high-purity crystals (>99% CBD).

Cannabis sativa has been used in Traditional Chinese Medicine (as 'mafen') and Ayurveda (as 'bhang') for over 2000 years to treat pain, inflammation, seizures, and anxiety. Historical texts like the Shennong Bencao Jing (100-200 AD) documented its use for 'wind-evil' disorders (epilepsy-like conditions) and rheumatism.Traditional Medicine

Research Narrative (Provisional)

Pivotal epilepsy trials include GWPCARE1 (n=214) showing 42.9% seizure reduction with 20mg/kg/day CBD (PMID: 27624143), and a 2020 meta-analysis of 8 RCTs (n=670) confirming significant seizure reduction (PMID: 32383718). Additional RCTs demonstrate efficacy in schizophrenia (n=88, PMID: 20815812) and social anxiety (n=11, PMID: 21307846), though evidence quality varies by condition.

Preparation & Dosage

Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.

Nutritional Profile

Cannabidiol (CBD) is a pure phytocannabinoid compound (molecular formula C21H30O2, MW 314.46 g/mol), not a food ingredient with classical macronutrient or micronutrient content. As an isolated compound, it contains no protein, carbohydrates, fiber, or minerals. Key physicochemical and bioactive properties: CBD concentration in pharmaceutical-grade isolate is ≥98% purity (e.g., Epidiolex contains 100mg/mL CBD in sesame oil with ethanol and strawberry flavoring as excipients). In hemp-derived full-spectrum extracts, CBD typically ranges from 2–20% by dry weight depending on cultivar. Bioactive compound profile: CBD itself is the primary active molecule; full-spectrum preparations also contain minor cannabinoids (CBG ~0.1–1%, CBN trace amounts, CBDV trace), terpenes (myrcene, limonene, linalool at 0.1–0.5% collectively), and flavonoids (cannflavin A and B, apigenin at trace levels <0.1%). Fat content: CBD isolate is lipophilic (log P ≈ 6.3), requiring a lipid carrier for formulation; sesame oil-based formulations contain approximately 79% unsaturated fatty acids (oleic ~40%, linoleic ~38%). Bioavailability is highly route-dependent: oral bioavailability is low at 6–19% due to extensive first-pass hepatic metabolism (CYP3A4, CYP2C19); sublingual administration improves bioavailability marginally to ~12–35%; inhalation yields highest bioavailability at 31–56% with Tmax ~3–10 minutes; lipid co-administration increases oral absorption by approximately 3-fold (Cmax increases from ~0.8 ng/mL to ~2.5 ng/mL at 10mg/kg dose). Half-life is 18–32 hours with chronic dosing. Protein binding is >94% (primarily albumin and lipoproteins). No significant vitamin or mineral content in isolated form.

Reported Mechanism (Provisional)

Mechanism of Action

CBD exerts its anticonvulsant and anxiolytic effects primarily by acting as a positive allosteric modulator of GABA-A receptors and an agonist at serotonin 5-HT1A receptors, reducing neuronal excitability and modulating fear-circuit signaling in the amygdala. Unlike THC, CBD has negligible affinity for CB1 and CB2 receptors but inhibits the reuptake and hydrolysis of the endogenous cannabinoid anandamide by blocking fatty acid amide hydrolase (FAAH), elevating anandamide tone. Additionally, CBD antagonizes GPR55 receptors and activates TRPV1 channels, contributing to its anti-inflammatory and nociceptive modulatory properties.

Clinical Narrative (Provisional)

The strongest evidence for CBD comes from three Phase 3 randomized controlled trials supporting FDA approval of Epidiolex (pharmaceutical-grade CBD) for Dravet syndrome and Lennox-Gastaut syndrome, where 20 mg/kg/day reduced median monthly convulsive seizures by 42.9% versus 17.2% for placebo (PMID: 27624143). A randomized, double-blind RCT in 88 patients with schizophrenia found adjunctive CBD (150–600 mg/day) significantly improved Positive and Negative Syndrome Scale (PANSS) scores compared to placebo (PMID: 20815812), though sample sizes remain modest and replication is needed. Acute anxiolytic effects have been demonstrated in simulated public speaking paradigms at single doses of 300 mg, but long-term RCT data for generalized anxiety disorder is limited. Overall, evidence is strong for epilepsy, moderate for psychosis, and preliminary for anxiety.

Also Known As

CBD2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediolhemp extractcannabis extractmafenbhangindustrial hemp cannabinoidnon-psychoactive cannabis compound

Explore the Full Encyclopedia

Browse evidence-gated ingredient records with transparent editorial and citation standards.

Browse Ingredients
These statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
From the Hermetica Research Desk

Research updates — and 25% off your first order

Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.

Educational content only — not medical advice.